NMRA — Neumora Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1885522 ·
Last close
$0.33
Market Cap
$62.85M
52W High
$3.65
52W Low
$0.30
ADV30
1,853,419
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -33,409,000 -34,440,000 95,046,000 85,654,000 76,495,000
Jun 2026 0 — -42,190,000 -43,082,000 125,249,000 116,834,000 80,730,000
Mar 2026 0 — -52,864,000 -53,458,000 153,877,000 147,072,000 83,197,000
Dec 2025 0 — -58,480,000 -59,450,000 191,047,000 182,530,000 87,176,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-180,520,000
Investing CF
$94,034,000
Financing CF
$78,797,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.23
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,280,689,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-206,258,000
Pretax Income TTM
$-212,715,000
Interest Exp TTM
$6,457,000
Analysts
6

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -241,156,000 -236,928,000 191,047,000 87,176,000 103,871,000 -206,440,000
Dec 2024 0 -263,464,000 -243,787,000 316,972,000 29,908,000 287,064,000 -182,936,000
Dec 2023 0 -252,098,000 -235,925,000 496,195,000 27,119,000 469,076,000 -163,278,000
Dec 2022 0 -135,870,000 -130,904,000 426,234,000 873,084,000 -446,850,000 -114,896,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$10,510,000
NetIncome TTM
$-212,745,000
OpCashFlow TTM
—
Assets (Latest)
$125,249,000
Forward EPS
$-0.67

Peers — same industry

TickerNameMarket CapLastDaily %
VISK Viskase Holdings, Inc. $63.49M $4.43 —
CSBR CHAMPIONS ONCOLOGY, INC. $63.91M $4.59 —
CRDF Cardiff Oncology, Inc. $65.85M $0.85 —
CGTX COGNITION THERAPEUTICS INC $59.90M $0.63 —
ATRA Atara Biotherapeutics, Inc. $66.22M $6.50 —

News headlines (Yahoo Finance, 1h cache)

Neumora Therapeutics (NMRA) Stock Fair Value Moves Lower After Analyst Target Cuts
2026-11-19 05:14 · Yahoo
Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 13:00 · Yahoo
Biotech Options Buzz: UTHR, NMRA, EWTX
2026-09-18 15:46 · Yahoo
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 11:00 · Yahoo
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
2026-07-27 11:00 · Yahoo
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
2026-07-11 15:08 · Yahoo
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy
2026-07-07 05:53 · Yahoo
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
2026-06-17 15:17 · Yahoo
Neumora depression drug fails; EnGene to cut 50% of staff
2026-06-16 09:08 · Yahoo
Three pivotal MDD trial failures for Neumora lead to staffing cuts
2026-06-16 15:58 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.